312 related articles for article (PubMed ID: 22336956)
1. Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Gong L; Thorn CF; Bertagnolli MM; Grosser T; Altman RB; Klein TE
Pharmacogenet Genomics; 2012 Apr; 22(4):310-8. PubMed ID: 22336956
[No Abstract] [Full Text] [Related]
2. Cyclooxygenase inhibitors and cardiovascular risk.
Andersohn F; Suissa S; Garbe E
JAMA; 2007 Feb; 297(6):586-7; author reply 587-8. PubMed ID: 17299191
[No Abstract] [Full Text] [Related]
3. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
4. Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?
Rodrigues AD; Yang Z; Chen C; Pray D; Kim S; Sinz M
Clin Pharmacol Ther; 2006 Sep; 80(3):298-301; author reply 301-02. PubMed ID: 16952496
[No Abstract] [Full Text] [Related]
5. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.
Stempak D; Bukaveckas BL; Linder M; Koren G; Baruchel S
Clin Pharmacol Ther; 2005 Sep; 78(3):309-10. PubMed ID: 16153401
[No Abstract] [Full Text] [Related]
6. Are COX-2 inhibitors safe for anyone.
Bloomfeld RS
Inflamm Bowel Dis; 2006 Sep; 12(9):922-3. PubMed ID: 16954813
[No Abstract] [Full Text] [Related]
7. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of celecoxib to prevent recurrent adenomas.
Psaty BM; Potter JD
N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
[No Abstract] [Full Text] [Related]
9. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.
Lundblad MS; Ohlsson S; Johansson P; Lafolie P; Eliasson E
Clin Pharmacol Ther; 2006 Mar; 79(3):287-8. PubMed ID: 16513453
[No Abstract] [Full Text] [Related]
10. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
Korzenik JR; Podolsky DK
Clin Gastroenterol Hepatol; 2006 Feb; 4(2):157-9. PubMed ID: 16469674
[No Abstract] [Full Text] [Related]
11. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
Guo ZR
Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
[No Abstract] [Full Text] [Related]
12. Fluvoxamine and celecoxib may have caused adverse events in an elderly patient.
Hori K; Konishi K; Akita R; Tanaka H; Hachisu M
Psychiatry Clin Neurosci; 2013 Jul; 67(5):363. PubMed ID: 23859666
[No Abstract] [Full Text] [Related]
13. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
Skarke C; Alamuddin N; Lawson JA; Cen L; Propert KJ; Fitzgerald GA
Clin Pharmacol Ther; 2012 Jun; 91(6):986-93. PubMed ID: 22278334
[TBL] [Abstract][Full Text] [Related]
14. The safety of celecoxib in ankylosing spondylitis treatment.
Poddubnyy DA; Song IH; Sieper J
Expert Opin Drug Saf; 2008 Jul; 7(4):401-9. PubMed ID: 18613804
[TBL] [Abstract][Full Text] [Related]
15. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.
Essex MN; Zhang RY; Berger MF; Upadhyay S; Park PW
Expert Opin Drug Saf; 2013 Jul; 12(4):465-77. PubMed ID: 23506230
[TBL] [Abstract][Full Text] [Related]
16. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.
Malhi H; Atac B; Daly AK; Gupta S
Postgrad Med J; 2004 Feb; 80(940):107-9. PubMed ID: 14970301
[TBL] [Abstract][Full Text] [Related]
17. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
Harirforoosh S; Aghazadeh-Habashi A; Jamali F
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):917-24. PubMed ID: 17002668
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib.
Cheung R; Lowry S
J R Soc Med; 2006 Jul; 99(7):336. PubMed ID: 16816261
[No Abstract] [Full Text] [Related]
19. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
[TBL] [Abstract][Full Text] [Related]
20. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
[Next] [New Search]
